Document:

Exhibit 10.3

                                VOTING AGREEMENT

      VOTING  AGREEMENT,  dated as of this 7th day of July, 2005  ("Agreement"),
among Chiste  Corporation,  a Nevada  corporation  ("Chiste"),  Keating  Reverse
Merger Fund, LLC, a Delaware limited liability company ("KRM Fund"), and each of
the persons  whose  signature  appears under the caption  "Shareholders"  on the
signature page hereof. For purposes of this Agreement,  KRM Fund and each person
whose signature appears on the signature page hereof shall be referred to herein
individually as "Shareholder" and collectively as the "Shareholders".

      WHEREAS,  as of the date hereof,  each  Shareholder  owns  beneficially of
record or has the power to vote,  or direct the vote of, shares of common stock,
par value $0.001 per share or shares of Series B  Convertible  Preferred  Stock,
par value $0.001 per share,  of Chiste as set forth opposite such  Shareholder's
name on Exhibit A hereto (all such shares and any shares of which  ownership  of
record or the power to vote is hereafter  acquired by the Shareholders,  whether
by purchase,  conversion or exercise, prior to the termination of this Agreement
being referred to herein as the "Shares");

      WHEREAS, Chiste, HydroGen, LLC ("HydroGen"),  the Shareholders (other than
KRM Fund) and other members of HydroGen have entered into an Exchange Agreement,
dated May 13, 2005 (as the same may be amended from time to time) (the "Exchange
Agreement"))  which  provides,  upon the terms  and  subject  to the  conditions
thereof,  for the  exchange of all of the  Interests of HydroGen for the Buyer's
Shares (the "Exchange");

      WHEREAS,  as a condition to the  consummation  of the Exchange  Agreement,
Chiste has requested that the  Shareholders  agree,  and the  Shareholders  have
agreed, severally, to enter into this Agreement; and

      WHEREAS,  the  capitalized  terms used but not  defined in this  Agreement
shall have the meanings ascribed to them in the Exchange Agreement;

      NOW,  THEREFORE,  in  consideration  of the  premises  and  of the  mutual
agreements  and  covenants set forth herein and in the Exchange  Agreement,  and
intending  to be legally  bound  hereby,  the  parties  hereto  hereby  agree as
follows:

                                   ARTICLE I
                   TRANSFER AND VOTING OF SHARES FOR DIRECTORS
                   -------------------------------------------

      SECTION 1.01 Transfer of Shares. Except as set forth in this Section 1.01,
during the term of this Agreement,  no Shareholder shall sell, transfer,  pledge
or otherwise dispose of any Shares. Notwithstanding the foregoing, the following
transfers  shall be permitted  under this  Agreement,  subject to the compliance
with applicable  securities  laws: (a) each  Shareholder  shall be permitted to,
without permission from Chiste or any other Shareholder, directly or indirectly,
to deposit any Shares of the Shareholder into a trust or similar  arrangement of
which the  Shareholder  or his  immediate  family (or in the case of a corporate

<PAGE>

entity its affiliates or owners) are the beneficiaries or principals in interest
or hold the controlling  interest, so long as the trust or holding entity agrees
in  writing to be bound by the terms of this  Agreement,  and (b)  transfer  the
Shares  by  will or the  laws of  intestacy,  so  long as the  administrator  or
beneficiary  agrees  in  writing  to be  bound by the  terms of this  Agreement.
Notwithstanding the foregoing,  KRM Fund, shall be permitted to sell,  transfer,
pledge or  otherwise  dispose  of any or all of its  Shares at any time  without
restriction and without permission from Chiste or any other Shareholder.

      Each certificate  evidencing Shares owned by each Shareholder  (other than
KRM Fund) and each  certificate  issued in exchange  for or upon the transfer of
any Shares owned by each  Shareholder  (other than KRM Fund) shall be stamped or
otherwise  imprinted with a legend (the "Legend") in substantially the following
form or to the following effect.

            "The securities represented by this certificate are
            subject to a Voting Agreement by and among the
            original holder of such securities, the issuer of
            such securities, and Keating Reverse Merger Fund, LLC
            and to an irrevocable proxy granted pursuant to the
            Voting Agreement. A copy of such agreement will be
            furnished without charge by issuer at its corporate
            offices, upon written request."

      SECTION 1.02 Vote in Favor of the Directors.  During the period commencing
on the date hereof and terminating one year thereafter, each Shareholder, in its
capacity as a Shareholder of Chiste (or successor),  agrees to vote (or cause to
be voted) all Shares  directly or indirectly  owned by the  Shareholder  or over
which the Shareholder has the beneficial  ownership or the right to vote and all
Shares  which  such  Shareholder  acquires  directly  or  indirectly  or has the
beneficial  ownership  or right to vote in the  future,  at any  meeting  of the
Shareholders of Chiste, and in any action by written consent of the Shareholders
of  Chiste,  in favor of the  election  of the  Director  Designees,  as defined
herein,  to the Board of  Directors  of Chiste and will not vote (or cause to be
voted) for the removal of the Director  Designees  from the Board of  Directors.
Any  Director  Designee may be removed from the Board of Directors in the manner
allowed  by law and  Chiste's  governing  documents,  but  with  respect  to the
Director  Designee  nominated  by KRM Fund  pursuant to Section 1.04 (c), in the
event such Director  Designee is removed as a director of the Company,  KRM Fund
shall  have  the  right  to  designate  and  nominate  such  removed  director's
replacement.

      SECTION 1.03 Size of Board of Directors.  The Shareholders  agree that the
Board of  Directors  of Chiste  shall  consist of five  persons  during the term
hereof, provided that the number of directors only may be increased or decreased
with the written consent of the KRM Fund during the term of this Agreement,  and
the  Shareholders  will take all such action to maintain the number of directors
at five or the number as agreed by KRM Fund.

      SECTION  1.04  Director  Designees.  The  Director  Designees  will  be as
follows:

            (a) so long as Joshua  Tosteson is employed by and a shareholder  of
Chiste, Joshua Tosteson and one person designated by Joshua Tosteson,  provided,
however, that if Joshua Tosteson elects, he may designate an additional director
in substitution for himself;

                                       2
<PAGE>

            (b) so  long as Leo  Blomen  is  employed  by and a  shareholder  of
Chiste, Leo Blomen and one person designated by Leo Blomen,  provided,  however,
that  if  Leo  Blomen  elects,  he  may  designate  an  additional  director  in
substitution for himself; and

            (c) for one person designated by KRM Fund.

      Neither   the   Shareholders,   nor  any  of  the   officers,   directors,
shareholders,   members,  managers,   partners,   employees  or  agents  of  any
Shareholder,  makes  any  representation  or  warranty  as  to  the  fitness  or
competence of any Director Designee to serve on the Board of Directors by virtue
of such  party's  execution  of this  Agreement  or by the act of such  party in
designating or voting for such Director Designee pursuant to this Agreement.

      SECTION  1.05  Term of  Agreement.  The  obligations  of the  Shareholders
pursuant to this Article I shall terminate on the first  anniversary of the date
of this Agreement.

                                   ARTICLE II
                          VOTING FOR CORPORATE ACTIONS
                          ----------------------------

      SECTION 2.01 Vote in Favor of Corporate  Matters.  During the term of this
Agreement,  each Shareholder  hereby agrees and covenants to vote or cause to be
voted all of his Shares then owned by him, or over which he has voting power, at
any regular or special meeting of shareholders, or, in lieu of any such meeting,
to  give  his  written   consent  in  any  action  by  written  consent  of  the
shareholders, in favor of each of the following items ("Actions"):

            (a) To approve a 1 for 25 reverse stock split with special treatment
for  certain  of  Chiste's  stockholders  to  preserve  round  lot  stockholders
("Reverse Split");

            (b) To approve the change of the name of Chiste;

            (c) All such other  actions as shall be  necessary  or  desirable in
connection  with or related to the  foregoing  actions in (a)  through (b) above
including, without limitation, any amendment to the articles of incorporation of
Chiste to effect the foregoing.

      SECTION 2.02 Grant of Proxy; Further Assurance. Each Shareholder,  by this
Agreement, with respect to all Shares over which it has voting authority and any
Shares  hereinafter  acquired by such  Shareholder over which it may have voting
authority, does hereby irrevocably constitute and appoint Joshua Tosteson and/or
Leo Blomen,  acting individually or jointly, or any nominee,  with full power of
substitution,  as his or its true and lawful attorney and proxy,  for and in his
or its name, place and stead, to vote each of such Shares as such  Shareholder's
proxy,  at every annual,  special or adjourned  meeting of the  shareholders  of
Chiste  (including  the  right to sign his or its name (as  Shareholder)  to any
consent,  certificate or other document relating to Chiste that may be permitted
or required by applicable  law) in favor of the adoption and approval of each of
the Actions.  This proxy extends to no other  matter,  except for the Actions as
enumerated  above.  Each Shareholder shall perform such further acts and execute
such further  documents and instruments as may reasonably be required to vest in
Chiste the power to carry out the provisions of this Agreement

                                       3
<PAGE>

      SECTION 2.03 Termination.  The obligations of each Shareholder pursuant to
this  Article  II  (including  the grant of the  proxy in  Section  2.02)  shall
terminate upon the adoption and approval of the Actions by the  shareholders  of
Chiste.

      SECTION 2.04 Obligations as Director and/or Officer. If Shareholder or any
of its affiliates or nominees is a member of the board of directors of Chiste (a
"Director")  or an officer of Chiste (an  "Officer"),  nothing in this Agreement
shall be deemed to limit or restrict  the  Director or Officer  acting in his or
her  capacity  as a  Director  or  Officer  of  Chiste,  as the case may be, and
exercising his or her fiduciary duties and responsibilities, it being agreed and
understood that this Agreement  shall apply to Shareholder  solely in his or her
capacity as a  shareholder  of Chiste and shall not apply to his or her actions,
judgments or decisions as a Director or Officer of Chiste.

                                  ARTICLE III
                         REPRESENTATIONS AND WARRANTIES;
                          COVENANTS OF THE SHAREHOLDERS
                          -----------------------------

      Each  Shareholder  hereby severally  represents  warrants and covenants to
Chiste and the other Shareholders as follows:

      SECTION 3.01  Authorization.  Such Shareholder has full legal capacity and
authority  to  enter  into  this  Agreement  and  to  carry  out  such  person's
obligations  hereunder.  This  Agreement has been duly executed and delivered by
such  Shareholder,  and (assuming due  authorization,  execution and delivery by
Chiste and the other Shareholders) this Agreement constitutes a legal, valid and
binding obligation of such Shareholder,  enforceable against such Shareholder in
accordance with its terms.

      SECTION 3.02 No Conflict; Required Filings and Consents.

            (a) The execution and delivery of this Agreement by such Shareholder
does not, and the  performance of this Agreement by such  Shareholder  will not,
(i)  conflict  with  or  violate  any  Legal  Requirement   applicable  to  such
Shareholder  or by which any property or asset of such  Shareholder  is bound or
affected,  or (ii) result in any breach of or  constitute a default (or an event
which with  notice or lapse of time or both would  become a default)  under,  or
give to others any right of termination, amendment, acceleration or cancellation
of, or result in the  creation of any  encumbrance  on any  property or asset of
such Shareholder,  including,  without limitation,  the Shares, pursuant to, any
note, bond, mortgage,  indenture,  contract,  agreement, lease, license, permit,
franchise or other instrument or obligation.

            (b) The execution and delivery of this Agreement by such Shareholder
does not, and the  performance of this Agreement by such  Shareholder  will not,
require any  consent,  approval,  authorization  or permit of, or filing with or
notification to, any governmental or regulatory authority,  domestic or foreign,
except (i) for applicable  requirements,  if any, of the Securities Exchange Act
of 1934, as amended (the "Exchange  Act"),  and (ii) where the failure to obtain
such consents, approvals,  authorizations or permits, or to make such filings or
notifications,  would not prevent or materially  delay the  performance  by such
Shareholder of such Shareholder's obligations under this Agreement.

                                       4
<PAGE>

      SECTION 3.03 Litigation. There is no private or governmental action, suit,
proceeding, claim, arbitration or investigation pending before any agency, court
or tribunal,  foreign or domestic,  or, to the knowledge of such  Shareholder or
any of such Shareholder's affiliates, threatened against such Shareholder or any
of such Shareholder's affiliates or any of their respective properties or any of
their  respective  officers or directors,  in the case of a corporate entity (in
their  capacities  as  such)  that,  individually  or in  the  aggregate,  would
reasonably be expected to materially delay or impair such Shareholder's  ability
to consummate the actions contemplated by this Agreement.  There is no judgment,
decree  or  order  against  such  Shareholder  or  any  of  such   Shareholder's
affiliates,   or,  to  the  knowledge  of  such   Shareholder  of  any  of  such
Shareholder's affiliates,  any of their respective directors or officers, in the
case of a corporate  entity (in their  capacities as such),  that would prevent,
enjoin,  alter or  materially  delay  any of the  actions  contemplated  by this
Agreement,  or that would  reasonably  be  expected  to have a material  adverse
effect on such Shareholder's  ability to consummate the actions  contemplated by
this Agreement.

      SECTION 3.04 Title to Shares. Such Shareholder is the legal and beneficial
owner of its Shares free and clear of all Encumbrances.

      SECTION 3.05 Absence of Claims.  Each  Shareholder has no knowledge of any
causes of action or other  claims that could have been or in the future might be
asserted  by  the  Shareholder  against  Chiste  or  any  of  its  predecessors,
successors, assigns, directors, employees, agents or representatives arising out
of facts or  circumstances  occurring at any time on or prior to the date hereof
and in any way relating to any duty or obligation of Chiste or any Shareholder.

                                   ARTICLE IV
                         REPRESENTATIONS AND WARRANTIES;
                               COVENANTS OF CHISTE
                               -------------------

      Chiste hereby  represents,  warrants and covenants to the  Shareholders as
follows:

      SECTION 4.01  Organization;  Authorization.  Chiste is a corporation  duly
incorporated,  validly  existing  and in good  standing  under  the  laws of the
jurisdiction  of its  incorporation  and has all requisite  corporate  power and
authority to own,  lease and operate its properties and to carry on its business
as it is now being  conducted.  Chiste  has all  necessary  corporate  power and
authority to execute and deliver this  Agreement and to perform its  obligations
hereunder and to consummate the transactions contemplated by this Agreement.

      SECTION   4.02   No    Conflict;    Required    Filings   and    Consents.

            (a) The execution and delivery of this Agreement by Chiste does not,
and the  performance  of this Agreement by Chiste will not, (i) conflict with or
violate  any  Legal  Requirement  applicable  to  Chiste  or by which any of its
property  or assets are bound or  affected,  or (ii)  result in any breach of or
constitute  a default  (or an event  which with  notice or lapse of time or both
would  become a  default)  under,  or give to others  any right of  termination,
amendment,  acceleration  or  cancellation  of, or result in the creation of any
encumbrance on any property or assets, including,  without limitation, any note,
bond,  mortgage,   indenture,   contract,  agreement,  lease,  license,  permit,
franchise or other instrument or obligation.

                                       5
<PAGE>

            (b) The execution and delivery of this Agreement by Chiste does not,
and the  performance of this Agreement by Chiste will not,  require any consent,
approval,  authorization  or permit of, or filing with or  notification  to, any
governmental  or  regulatory  authority,  domestic  or  foreign,  except (i) for
applicable  requirements,  if any, of the  Securities  Exchange Act of 1934,  as
amended  (the  "Exchange  Act"),  and (ii)  where the  failure  to  obtain  such
consents,  approvals,  authorizations  or  permits,  or to make such  filings or
notifications,  would not prevent or materially  delay the performance by Chiste
of its obligations under this Agreement.

      SECTION 4.03 Litigation. There is no private or governmental action, suit,
proceeding, claim, arbitration or investigation pending before any agency, court
or tribunal,  foreign or domestic,  or, to the  knowledge of Chiste,  threatened
against  Chiste or any of its properties or any of its officers or directors (in
the capacities as such) that, individually or in the aggregate, would reasonably
be expected to materially  delay or impair  Chiste's  ability to consummate  the
actions  contemplated by this Agreement.  There is no judgment,  decree or order
against Chiste, or, to the knowledge of Chiste, any of its directors or officers
(in the  capacities as such),  that would prevent,  enjoin,  alter or materially
delay  any  of the  actions  contemplated  by  this  Agreement,  or  that  would
reasonably be expected to have a Material  Adverse Effect on Chiste's ability to
consummate the actions contemplated by this Agreement.

                                   ARTICLE V
                               GENERAL PROVISIONS
                               ------------------

      SECTION 5.01 Notices.  All notices and other  communications given or made
pursuant  hereto  shall be in writing and shall be given (and shall be deemed to
have been duly given upon receipt) by delivery in person,  by overnight  courier
service,  by telecopy,  or by  registered or certified  mail  (postage  prepaid,
return receipt requested) to the respective  parties at the following  addresses
(or at such other  addresses as shall be specified by notice given in accordance
with this Section 5.01):

                  (a) If to Chiste:

                                    Chiste Corporation
                                    Attention, Kevin R. Keating, President
                                    936A Beachland Boulevard, Suite 13
                                    Vero Beach, FL USA 32963

                                    with a mandatory copy to

                                    Graubard Miller
                                    Attention:  Andrew Hudders, Esq.
                                    405 Lexington Avenue
                                    New York, NY 10174-1901
                                    Facsimile:  (212) 818-8881

                                       6
<PAGE>

                  (b) If to any Shareholder (other than KRM Fund):

                                    HydroGen, LLC
                                    Attention: Joshua Tosteson
                                    1801 Route 51 South
                                    Jefferson Hills, PA 15025
                                    Facsimile: _______________

                  (c) If to KRM Fund:

                                    Keating Reverse Merger Fund, LLC
                                    Mr. Timothy J. Keating, Manager
                                    5251 DTC Parkway, Suite 1090
                                    Greenwood Village, CO USA 80111-2739
                                    Facsimile: (720) 889-0135

      SECTION 5.02  Headings.  The headings  contained in this Agreement are for
reference  purposes  only  and  shall  not  affect  in any  way the  meaning  or
interpretation of this Agreement.

      SECTION  5.03  Severability.  If any  term  or  other  provision  of  this
Agreement is invalid,  illegal or incapable of being enforced by any rule of law
or public policy,  all other  conditions and provisions of this Agreement  shall
nevertheless  remain in full force and effect so long as the  economic  or legal
substance of the transactions  contemplated hereby is not affected in any manner
materially  adverse to any party. Upon such determination that any term or other
provision is invalid, illegal or incapable of being enforced, the parties hereto
shall  negotiate  in good  faith to modify  this  Agreement  so as to effect the
original  intent of the parties as closely as  possible  to the  fullest  extent
permitted  by  applicable  law in an  acceptable  manner  to the  end  that  the
transactions contemplated hereby are fulfilled to the extent possible.

      SECTION  5.04 Entire  Agreement.  This  Agreement  constitutes  the entire
agreement of the parties and supersedes all prior  agreements and  undertakings,
both written and oral, between the parties,  or any of them, with respect to the
subject matter hereof.  This Agreement may not be amended or modified  except in
an instrument in writing signed by, or on behalf of, the parties hereto.

      SECTION  5.05  Specific   Performance.   The  parties  hereto  agree  that
irreparable damage would occur in the event that any provision of this Agreement
was not performed in accordance with the terms hereof and that the parties shall
be entitled  to specific  performance  of the terms  hereof,  in addition to any
other remedy at law or in equity.

      SECTION  5.06  Governing  Law.  This  Agreement  shall be governed by, and
construed in accordance  with,  the laws of the State of Colorado  applicable to
contracts executed in and to be performed in that State.

                                       7
<PAGE>

      SECTION  5.07  Disputes.  All  actions and  proceedings  arising out of or
relating to this  Agreement  shall be heard and  determined  exclusively  in any
state or federal court in Colorado.

      SECTION 5.08 No Waiver. No failure or delay by any party in exercising any
right, power or privilege  hereunder shall operate as a waiver thereof nor shall
any single or partial  exercise  thereof  preclude any other or further exercise
thereof or the exercise of any other right,  power or privilege.  The rights and
remedies  herein provided shall be cumulative and not exclusive of any rights or
remedies provided by law.

      SECTION 5.09  Counterparts.  This Agreement may be executed in one or more
counterparts, and by the different parties hereto in separate counterparts, each
of which when executed  shall be deemed to be an original but all of which taken
together shall constitute one and the same agreement.

      SECTION 5.10 Waiver of Jury Trial. Each of the parties hereto  irrevocably
and unconditionally waives all right to trial by jury in any action,  proceeding
or counterclaim (whether based in contract, tort or otherwise) arising out of or
relating  to  this  Agreement  or the  Actions  of  the  parties  hereto  in the
negotiation, administration, performance and enforcement thereof.

      SECTION 5.11 Exchange Agreement.  All references to the Exchange Agreement
herein shall be to such agreement as may be amended by the parties  thereto from
time to time.

                           [Signature page(s) follows]

                                       8
<PAGE>

      IN WITNESS  WHEREOF,  the parties have executed  this  Agreement as of the
date first written above.

CHISTE CORPORATION

By:______________________________________________
       Kevin R. Keating, President

KEATING REVERSE MERGER FUND, LLC

By:______________________________________________
        Timothy J. Keating, Manager

SHAREHOLDERS:                                   SHAREHOLDERS:

FuelCell Holdings, LLC                          HMR, LP

By: _______________________________             By: __________________________

Title: ____________________________             Title: _________________________

-----------------------------------             -------------------------------
Joshua Tosteson                                 Leo Blomen

-----------------------------------             -------------------------------
Andrew Thomas                                   David Brewster

-----------------------------------             -------------------------------
Gregory Morris                                  Scott Schecter

-------------------------------
Brian Bailys

                                       9
<PAGE>

                 COUNTERPART SIGNATURE PAGE TO VOTING AGREEMENT
                                FOR SHAREHOLDERS

      This  Voting   Agreement,   dated  as  of  this  __  day  of  July,   2005
("Agreement"),  among  Chiste  Corporation,  a  Nevada  corporation  ("Chiste"),
Keating Reverse Merger Fund,  LLC, a Delaware  limited  liability  company ("KRM
Fund"),  and each of the  persons  whose  signature  appears  under the  caption
"Shareholders"  on the  signature  page  hereof,  may be  signed  in one or more
counterparts,  each of which  shall be  deemed  to be an  original  copy of this
Agreement and all of which,  when taken together,  shall be deemed to constitute
one and the same Agreement.

      IN WITNESS  WHEREOF,  the  undersigned,  being a Shareholder of Chiste has
executed  this  Agreement on and effective for all purposes as of the date first
written above.

                                            SHAREHOLDER:

                                            ---------------------------

                                       10EXHIBIT 10.11

                                     Print Name of Subscriber __________________

                                         Amount of Investment __________________

                             SUBSCRIPTION AGREEMENT

HydroGen, LLC ("Company") and the Investor hereby agree as follows:

1.  Subscription  for  Securities.  I  (sometimes  referred  to  herein  as  the
"Investor")  hereby  subscribe  for and agree to purchase  the number of limited
liability  units  ("Units")  of the  Company,  in the number as set forth on the
signature  page  hereto,  upon  the  terms  and  conditions  described  in  this
Agreement. The price per-Unit is $125,000.

      The Units are being offered in a private  placement in accordance with the
terms set forth in the Confidential  Private Placement  Memorandum dated May 13,
2005  ("Memorandum").  Capitalized  terms not defined  herein will have the same
meaning  as set  forth in the  Memorandum.  The  Units  will  have the terms and
conditions  described  herein and in the Memorandum.  Battenkill  Capital,  Inc.
("Battenkill")  is acting as exclusive  placement  agent for the  offering.  The
Company  will pay  Battenkill a fee, as  described  in the  Memorandum,  for its
services.

      In  connection  with the  offering of the Units and as a condition  to the
consummation   of  the  offering,   the  Company  will  be  acquired  by  Chiste
Corporation,  a Nevada  corporation  ("Chiste") by an exchange  ("Exchange")  of
membership  units for shares of Series B Convertible  Preferred  Stock of Chiste
("Preferred  Stock"),  pursuant  to an  Exchange  Agreement,  a form of which is
included in the Memorandum and a copy of which the Investor acknowledges receipt
("Exchange Agreement"). Pursuant to the Exchange Agreement, immediately after my
subscription is accepted, the Units for which I subscribe will be converted into
shares of Preferred  Stock,  at the conversion  rate set forth in the Memorandum
and I will receive certificates  representing the Preferred Stock instead of the
Units.

      Upon  consummation  of the  offering and the  Exchange,  each Unit will be
exchanged  for  4,239.425  shares of Preferred  Stock (if the minimum  under the
offering is sold) and 3,610.903  shares of Preferred Stock (if the maximum under
the offering is sold).  Each share of Preferred  Stock will be convertible  into
185.35215  shares of common  stock of Chiste,  subject to  adjustment.  Once the
proposed one for 25 reverse split is consummated,  each share of Preferred Stock
will convert into 7.4140860 shares of common stock of Chiste.

      As a further  condition to the  consummation  of the  offering,  after the
Exchange,  there  will  be an  investment  in  Chiste  by  one or  more  related
institutional  investors of not less than $7,000,000 such that their  investment
("Institutional  Investment")  combined with the minimum under the offering will
aggregate  not less than  $12,000,000  being  invested in cash in Chiste and the
Company  (excluding  any  Units  sold  for  conversion  of  Company  debt).  The
investment by the  institutional  investors will be contingent on  subscriptions
for the minimum offering amount being received by the Company. The investment by
the institutional  investors will be governed by separate investment  agreements
which may have different terms than this Agreement.

<PAGE>

2. Offering Period.  The Units will be offered for sale until the earlier of the
consummation  of the  Exchange or May 31, 2005.  Battenkill  and the Company may
agree to extend the May 31, 2005 date for up to an additional  60 days,  without
notice to subscribers, at their discretion (such date, as it may be extended, is
referred to as the "Termination Date").

3. Investor Delivery of Documents and Payment. I hereby tender to Battenkill, as
placement  agent for the Company (i) the full  purchase  price of the Units I am
purchasing,  (ii) one manually executed copy of this Subscription Agreement with
the appropriate  questionnaires therein completed,  and (iii) the completed NASD
questionnaire  attached  to this  Subscription  Agreement.  Simultaneously  with
submitting this Subscription  Agreement,  I am wiring the subscription amount in
accordance with the directions on the cover sheet,  and have contacted Ms. Robyn
Harrington of Battenkill at (802) 549-5400.  My subscription  funds will be held
in an account maintained by Battenkill Capital, Inc. with Factory Point National
Bank, with an address at P.O. Box 1567, Manchester Center,  Vermont 05255, under
the account name, "HydroGen Escrow Account." Prior to the earlier of the Closing
(as defined in Section 5 hereof) or the Termination Date, my subscription amount
will be held in the account which is a non-interest  bearing  segregated account
at Factory  Point  National  Bank. If the Company does not receive and accept my
subscription by the earlier of the Closing or the  Termination  Date, my payment
will be returned to me without interest or deduction.

4. Acceptance or Rejection of Subscription.  The Company and Battenkill have the
right to reject  this  subscription  for the Units,  in whole or in part for any
reason and at any time prior to the Closing, notwithstanding prior receipt by me
of notice of  acceptance of my  subscription.  In the event my  subscription  is
rejected,  my  payment  will be  returned  promptly  to me without  interest  or
deduction  and this  Subscription  Agreement  will have no force or effect.  The
Units  subscribed  for herein will not be deemed  issued to or owned by me until
one  copy  of  this   Subscription   Agreement  has  been  executed  by  me  and
countersigned by the Company and the Closing with respect to my subscription has
occurred.

5.  Closing and  Delivery of  Securities.  The offering is being made on a "best
efforts,  $5,000,000 minimum,  $10,000,000 maximum" basis;  however, the size of
the  offering  may be  increased  without  notice  to  Investors.  Officers  and
directors of the Company and affiliates of Battenkill may invest in the offering
whose subscription  funds will count towards the minimum,  and any conversion of
the 6% Convertible  Promissory  Notes by Company  members will not count towards
the minimum but such  conversion  will be included in the offering.  The closing
and the release of funds to the Company or its  designees is  contingent  on the
consummation  of the  Exchange  and the  Institutional  Investment.  The closing
("Closing") may occur at any time, as determined jointly by the Company,  Chiste
and  Battenkill,  after  satisfaction  of  the  closing  conditions  before  the
Termination  Date,  as herein set forth and in the  Exchange  Agreement.  In the
event my  subscription  is accepted  and there is a Closing,  my payment will be
released to the Company or its designees and the  certificates  representing the
Preferred  Stock of Chiste will be delivered  promptly in due course to me along
with a fully executed version of this Agreement.

6.  Offering to  Accredited  Investors.  This  offering is limited to accredited
investors as defined in Section 2(15) of the  Securities Act of 1933, as amended
("Securities  Act"),  and Rule 501  promulgated  thereunder,  and is being  made
without  registration  under the  Securities Act in reliance upon the exemptions
contained  in  Sections  3(b),  4(2)  and/or  4(6)  of the  Securities  Act  and
applicable state securities laws. As indicated by the responses on the signature
page  hereof,  the  Investor  is an  accredited  investor  within the meaning of
Section 2(15) of the Securities Act and Rule 501 promulgated thereunder.

7. Registration Rights.

      7.1.  Filing of  Registration  Statement.  Chiste,  after the  Closing and
acquisition  of the Company by means of the  Exchange,  is hereby  obligated  to
include for resale by the  investors  in the offering  (or  subsequent  holders,
referred to  together  as the  "Holders")  and by the  Institutional  Investment
holders,  the Common Stock into which the Preferred  Stock is  convertible  in a
registration  statement  under the  Securities Act filed with the Securities and
Exchange  Commission  ("Commission")  that it will initially file not later than
the later of 95 days after the consummation of the offering or 45 days after the
filing by Chiste of the  financial  statements  of the  Company  and Chiste on a
combined  basis in a Form 8-K or other  periodic  report.  (The Common  Stock is
being referred to in connection with the registration rights as the "Registrable

                                       2
<PAGE>

Securities").  In addition, Chiste will "blue sky" the reoffer and resale of the
Registrable   Securities  in  such  state   jurisdictions  as  Battenkill  shall
reasonably  request,  provided  that  Chiste  and the  Company  will not have to
qualify to do business in such state or consent to service of process other than
on a Form  U-2.  The  registration  statement  will  be for  the  resale  of the
Registrable  Securities  in the  hands  of  Holders  (or  their  transferees  as
permitted  by  federal   securities   laws).   All  costs  associated  with  the
registration of the Registrable Securities, other than brokerage commissions and
counsel  costs  incurred  by the  holders  in  connection  with  resales  of the
Registrable  Securities which shall be the responsibility of the Holders,  shall
be borne by Chiste.  Chiste  promptly  will  deliver such  reasonable  number of
prospectuses  relating to the resale of the Common Stock as the Holder  requests
after   effectiveness  of  the   registration   statement  for  the  Registrable
Securities.

      7.2.  Effective  and Current.  Chiste will use its  reasonable  commercial
efforts to keep the  registration  statement  which  registers  the  Registrable
Securities  pursuant hereto effective and the related  prospectus  current until
the earlier of the date by which all of the Registrable Securities of the Holder
have been sold or the date that  Registrable  Securities of a Holder may be sold
pursuant to Rule 144  promulgated  under the Securities Act (even though at such
date all the  Registrable  Securities  may not be eligible for public sale under
Rule 144).

      7.3.  Amended  Prospectus.  Chiste will notify Holder of such  Registrable
Securities  as  expeditiously  as possible  following the  effectiveness  of the
registration  statement  on which the  Registrable  Securities  are  registered,
and/or of any request by the  Commission  for the amending or  supplementing  of
such  registration  statement or  prospectus.  If the  prospectus  is amended to
comply with the requirements of the Securities Act, the Holder,  if requested by
Chiste,  will immediately cease making offers of the Registrable  Securities and
return all prospectuses to Chiste,  and Chiste will promptly provide the Holders
with revised  prospectuses  to enable the Holders to resume making offers of the
Registrable  Securities.  Chiste  will  promptly  notify  the  Holder,  if after
delivery of a prospectus to the Holder,  that, in the judgment of Chiste,  it is
advisable  to  suspend  use of the  prospectus  delivered  to the  Holder due to
pending  material  developments  or other events that have not yet been publicly
disclosed and as to which Chiste believes public disclosure would be detrimental
to Chiste.  Upon  receipt of such  notice,  each such  Holder  will  immediately
discontinue any sales of Registrable  Securities  pursuant to such  registration
statement  until such Holder has received  copies of a  supplemented  or amended
prospectus  or until such  Holder is advised in writing by Chiste  that the then
current  prospectus  may be used and has received  copies of any  additional  or
supplemental  filings that are incorporated or deemed  incorporated by reference
in such prospectus. Notwithstanding anything to the contrary herein, Chiste will
not exercise its rights under this  subsection to suspend  sales of  Registrable
Securities for a period in excess of 60 days in any 365-day period.

      7.4. Indemnification.

            (a) Chiste will indemnify the Holder of the  Registrable  Securities
to be sold pursuant to any registration  statement  hereunder,  the officers and
directors of Holder,  each underwriter of such  Registrable  Securities and each
person, if any, who controls such Holders or underwriters  within the meaning of
Section 15 of the Securities Act or Section 20(a) of the Securities Exchange Act
of 1934, as amended ("Exchange Act"), or any state securities law or regulation,
against all loss, claim, damage,  expense or liability (including all reasonable
attorneys'  fees  and  other  expenses  reasonably  incurred  in  investigating,
preparing or defending against any claim whatsoever  incurred by the indemnified
party in any action or  proceeding  between  (A) the  indemnified  party and any
third party or otherwise or (B) the  indemnitor and the  indemnified  party only
with  respect  to  an  action  or  proceeding  to  enforce  the  indemnification
provisions of this Section  7.4(a) to which any of them may become subject under
the  Securities  Act, the Exchange Act or any other  statute or at common law or
otherwise  under  the laws of any of the  United  States or  foreign  countries,
arising from such  registration  statement or based upon any untrue statement or
alleged  untrue  statement of a material fact  contained in (x) any  preliminary
prospectus,  the registration statement or prospectus (as from time to time each
may be amended and supplemented); (y) any post-effective amendment or amendments
or any new  registration  statement  and  prospectus  in which is  included  the
Registrable  Securities;  or (z) any  application  or other  document or written
communication  (collectively called  "application")  executed by Chiste or based
upon written  information  furnished by Chiste in any  jurisdiction  in order to
qualify the  Registrable  Securities  under the securities laws thereof or filed
with the Commission, any state securities commission or agency or any securities

                                       3
<PAGE>

exchange;  or the  omission or alleged  omission  therefrom  of a material  fact
required to be stated  therein or necessary to make the statements  therein,  in
light of the  circumstances  under which they were made, not misleading,  unless
such  statement or omission is made in reliance  upon,  and in conformity  with,
written  information  furnished to Chiste by and with respect to such registered
holders  ("Purchaser   Information")   expressly  for  use  in  any  preliminary
prospectus,  the  registration  statement  or  prospectus,  or any  amendment or
supplement  thereof,  or in any  application,  as the case may be, or unless the
indemnities  failed  to  deliver  a  final  prospectus  in  which  the  material
misstatement or omission was corrected.  Subject to the foregoing  provisions of
this  paragraph,  Chiste will reimburse such Holder,  underwriter  and each such
controlling  person for any legal or any other expenses  reasonably  incurred by
such Holder,  underwriter or controlling person in connection with investigating
or defending any such loss, claim,  damage,  liability or action.  Chiste agrees
promptly to notify Holder of the  commencement  of any litigation or proceedings
against  Chiste or any of its  officers,  directors  or  controlling  persons in
connection with the issue and sale or resale of the Registrable Securities or in
connection with the registration  statement or prospectus.

            (b) The Holder  agree to indemnify  and hold  harmless  Chiste,  the
officers and  directors of Chiste and each person,  if any, who controls  Chiste
within the meaning of Section 15 of the  Securities  Act or Section 20(a) of the
Exchange  Act or is  controlled  by Chiste,  against  all loss,  claim,  damage,
expense or liability to which Chiste or such  controlling  or controlled  person
may  become  subject,  under the  Securities  Act or  otherwise  insofar as such
losses, claims, damages, expenses or liabilities (or actions in respect thereof)
arise out of or are based upon written Purchaser Information that is included or
relied  upon by  Chiste  in the  registration  statement  or  prospectus  or any
amendment  or  supplement  thereto  or in any  application;  and will  reimburse
Chiste,  officer,  director  and each such  controlling  person for any legal or
other expenses  reasonably  incurred by them in connection with investigating or
defending any such loss, claim, damage,  liability or action, provided that such
loss, claim, damage, expense or liability is found ultimately to arise out of or
be based upon such written Purchaser Information.

      7.5.  Assumption  of  Defense.   Any  party  entitled  to  indemnification
hereunder  ("Indemnified Party") will permit Chiste to assume the defense of any
such claim or any litigation  resulting  therefrom;  provided,  that counsel for
Chiste,  who will  conduct  the  defense  of such claim or  litigation,  will be
approved by the  Indemnified  Party (whose  approval  shall not be  unreasonably
withheld). The Indemnified Party may participate in such defense at such party's
expense; provided,  however, that Chiste will pay such expense if representation
of  such  Indemnified   Party  by  the  counsel  retained  by  Chiste  would  be
inappropriate  due to  actual  or  potential  differing  interests  between  the
Indemnified  Party and any  other  party  represented  by such  counsel  in such
proceeding; provided further that in no event will Chiste be required to pay the
expenses  of  more  than  one law  firm  per  jurisdiction  as  counsel  for the
Indemnified  Party.  Chiste is also responsible for the expenses of such defense
if Chiste does not elect to assume such defense.  Chiste,  in the defense of any
such claim or litigation  may not,  except with the consent of each  Indemnified
Party,  consent to entry of any judgment or enter into any settlement which does
not  include as an  unconditional  term  thereof  the giving by the  claimant or
plaintiff to such  Indemnified  Party of a release from all liability in respect
of such claim or litigation,  and no  Indemnified  Party may consent to entry of
any  judgment  or settle  such claim or  litigation  without  the prior  written
consent of the Company, which consent may not be unreasonably withheld.

                                       4
<PAGE>

      7.6.  Successors.  The registration  rights granted to the Holder inure to
the  benefit  of  all  the  Holder's  successors,   heirs,  pledges,  assignees,
transferees  and  purchasers  of  the  Common  Stock,   Warrants  or  underlying
securities, subject to the limitations of the federal securities laws.

      7.7.  Short Selling.  The Holder agrees not to use any of the  Registrable
Securities to cover any short  position in the Common Stock if doing so would be
in violation of the  applicable  securities  laws and otherwise will comply with
federal securities laws in the holding and sale of the Registrable Securities.

      7.8.  Voting and Selling  Authority over  Registrable  Securities.  Unless
otherwise  specified on the  signature  page in the space  provided,  the person
executing this  Subscription  Agreement,  subject to the voting agreement herein
contained,  has or will  have  the  voting  and  investment  authority  over the
Registrable Securities in respect of the Investor,  subject to the provisions of
the voting  agreement herein set forth. If that person shall no longer have such
authority, Chiste and the Company will be immediately notified. Until receipt of
such notice, Chiste and the Company may rely on this representation for purposes
of the registration statement and include such person's name in the registration
statement.

      7.9. Liquidated  Damages.  Chiste and Holder agree that Holder will suffer
damages  if  Chiste  fails to  fulfill  its  obligations  pursuant  to the first
sentence of Section  7.1 hereof and that it would not be  possible to  ascertain
the extent of such damages with precision.  Accordingly, Chiste hereby agrees to
pay  liquidated  damages  ("Liquidated  Damages") to Holder if the  registration
statement  is not  filed by  Chiste  within  the time  period  set forth in such
provision ("Filing Default").  In the event of a Filing Default, Chiste shall as
Liquidated Damages pay to Holder, for each 30 day period of a Filing Default, an
amount in cash equal to 1% of the  aggregate  amount  invested  by Holder or his
predecessor  pursuant to this  Agreement up to a maximum of 10% of the aggregate
amount  invested.  The Company shall pay the Liquidated  Damages on the later of
the 95th day after the  consummation  of the  offering or the 45th day after the
filing by Chiste of the  financial  statements  of the  Company  and Chiste on a
combined  basis in a Form  8-K or  other  periodic  report,  and  each  30th day
thereafter  until  the  registration  statement  is filed  with the  Commission.
Notwithstanding  the  foregoing,  Chiste shall have no liability for  Liquidated
Damages to any Holder who is not named in a  registration  statement as a result
of any  action or  inaction  of such  Holder  or as a result  of any  limitation
imposed by the Commission in respect of the Holder either as to the Holder or as
to the any securities included on the registration statement or any other person
whose  securities  are  to  be  included  on  the  registration  statement.  The
Liquidated  Damages  payable  herein  shall  apply on a pro rata  basis  for any
portion of a 30-day period of a Filing Default.

8. Surrender Contingency.

      8.1.  Relinquishment  of  Securities.  I agree that,  if the NASD will not
grant clearance of the registration  statement of Registrable Securities because
the Units,  Preferred  Stock or Common Stock held by me are  considered  part of
underwriters'  compensation,  I will surrender and relinquish  said  Registrable
Securities to Chiste or, alternatively,  at the election of Battenkill, transfer
such securities to a third party designated by Battenkill (subject to an opinion
from  Chiste's  counsel that such transfer may be made to such third party under
the  securities  laws),  in exchange for the remittal to me of the  subscription
price paid hereunder either by Chiste,  upon the surrender and relinquishment of
such securities, or by such third party, upon the transfer of such securities to
such third party.  Battenkill is a third-party  beneficiary  of this Section 8.1
and this  Section 8.1 may not be modified or amended  without the prior  written
agreement of Battenkill.  I hereby  authorize  Battenkill to act as my agent and
attorney-in-fact  to surrender or transfer the  securities  to Chiste or a third
party and to receive and hold on my behalf the subscription price to be remitted
to me by Chiste, upon the surrender and relinquishment of such securities, or by
such third party, upon the transfer of such securities to such third party.

9. Investor Representations and Warranties.

      9.1. Investor Representations.  I am aware that, except for any rescission
rights that may be provided under  applicable laws, I am not entitled to cancel,
terminate or revoke this  subscription,  and any  agreements  made in connection
herewith will survive my death or disability.  In order to induce the Company to
issue and sell the Units to me and Chiste to issue in the exchange the Preferred
Stock and  thereafter  the Common  Stock upon its  conversion,  I represent  and
warrant that the  information  relating to me stated herein is true and complete
as of the date  hereof and will be true and  complete as of the date on which my
purchase of Units becomes effective.  If, prior to the final consummation of the
offer and sale of the Units,  there should be any change in such  information or
any of the information  becomes  incorrect or incomplete,  I agree to notify the
Company and Chiste and supply the Company and Chiste  promptly  with  corrective
information.

                                       5
<PAGE>

      9.2. Information About the Company and Chiste.

            (a) I have read this subscription agreement, the Memorandum relating
to this  offering  and all  exhibits  listed  therein and fully  understand  the
Memorandum,  including the "Risk Factors"  contained  therein.  I understand the
nature of the exchange  transaction with Chiste and the prospective  business of
the Company  after the  exchange.  I have been given access to full and complete
information regarding the Company and Chiste and have utilized such access to my
satisfaction  for the  purpose of  verifying  the  information  included  in the
Memorandum  and  exhibits  thereto,  and I have  either  met with or been  given
reasonable  opportunity  to meet with officers of the Company for the purpose of
asking reasonable questions of such officers concerning the terms and conditions
of the offering of the Units and the business and  operations of the Company and
Chiste and all such questions have been answered to my full satisfaction. I also
have been given an opportunity to obtain any additional relevant  information to
the extent  reasonably  available to the Company and Chiste. I have received all
information  and  materials  regarding  the  Company  and  Chiste  that  I  have
reasonably  requested.  After my reading of the materials  about the Company and
Chiste, I understand that there is no assurance as to the future  performance of
the Company and Chiste.

            (b) I have received no  representation or warranty from the Company,
Chiste or Battenkill or any of their respective officers,  directors,  employees
or agents in respect of my  investment  in the Company  and after the  exchange,
Chiste. I am not  participating in the offering as a result of or subsequent to:
(i) any advertisement,  article,  notice or other communication published in any
newspaper,  magazine or similar media or broadcast over television, radio or the
Internet or (ii) any seminar or meeting whose attendees have been invited by any
general solicitation or general advertising.

      9.3. Speculative Investment.  I am aware that the Units (and the Preferred
Stock and Common  Stock into which they will be exchanged  or  converted)  are a
speculative  investment that involves a high degree of risk  including,  but not
limited to, the risk of losses from operations of the Company and the total loss
of my investment. I have such knowledge and experience in financial and business
matters as to be capable of evaluating  the merits and risks of an investment in
the Units  (and the  Preferred  Stock and  Common  Stock into which they will be
exchanged  or  converted)  and  have  obtained,   in  my  judgment,   sufficient
information  from the Company and Chiste to evaluate  the merits and risks of an
investment  in the  Company  and Chiste.  I have not  utilized  any person as my
purchaser  representative  (as  defined  in  Regulation  D) in  connection  with
evaluating   such  merits  and  risks  and  have  relied   solely  upon  my  own
investigation  in making a decision to invest in the Company.  I have been urged
to  seek  independent  advice  from my  professional  advisors  relating  to the
suitability  of an  investment  in the  Company in view of my overall  financial
needs and with respect to the legal and tax implications of such  investment.  I
believe that the investment in the Units (and  subsequently  the Preferred Stock
and Common  Stock) is suitable for me based upon my  investment  objectives  and
financial  needs,  and I have  adequate  means  for  providing  for  my  current
financial needs and contingencies and have no need for liquidity with respect to
my investment in the Company and Chiste.  The investment in the Company does not
constitute all or substantially all of my investment portfolio.

      9.4.  Restrictions on Transfer. I understand that (i) none of the Units to
be issued in the offering and the Preferred  Stock and Common Stock to be issued
in the exchange and conversion have been registered  under the Securities Act or
the securities  laws of certain states in reliance on specific  exemptions  from
registration,  (ii) no  securities  administrator  of any  state or the  federal
government  has  recommended  or endorsed  this  offering or made any finding or
determination relating to the fairness of an investment in the Company or Chiste

                                       6
<PAGE>

and  (iii)  the  Company  and  Chiste  are  relying  on my  representations  and
agreements for the purpose of  determining  whether this  transaction  meets the
requirements of the exemptions  afforded by the Securities Act and certain state
securities  laws. Other than as set forth herein, I acknowledge that there is no
assurance  that the Company or Chiste will file any  registration  statement for
the securities I am purchasing, that such registration statement, if filed, will
be declared effective or, if declared effective, that the Company or Chiste will
be able to keep it effective  until I sell the  securities  registered  thereon.
Furthermore,  I agree to furnish the  Company  and Chiste with such  information
regarding  myself and the  distribution of the securities  proposed by me as the
Company or Chiste may request in connection with any registration, qualification
or compliance with the Company's or Chiste's registration  obligations set forth
herein.

      9.5.   Investment   Representation.   I  am  purchasing   the  Units  (and
subsequently  the  Preferred  Stock and  Common  Stock) for my own  account  for
investment  and  not  with a view  to,  or for  sale  in  connection  with,  any
subsequent  distribution  of the securities,  nor with any present  intention of
selling  or  otherwise  disposing  of all  or any  part  of  the  securities.  I
understand  that,  although there is a public market for Common Stock of Chiste,
there is no assurance  that such market will  continue.  I understand  and agree
that the Units,  Preferred  Stock and Common  Stock  cannot be resold,  pledged,
assigned or otherwise disposed of unless they are subsequently  registered under
the Securities Act and under applicable securities laws of certain states, or an
exemption from such registration is available.  I understand that, except as set
forth  herein,  the Company and Chiste are under no  obligation  to register the
securities  or  to  assist  me  in  complying   with  any  exemption  from  such
registration  under the  Securities Act or any state  securities  laws. I hereby
authorize the Company and Chiste to place a legend denoting the  restrictions on
the certificates representing the Units, Preferred Stock and Common Stock.

      9.6.  Entity  Authority.  If the Investor is a  corporation,  partnership,
company, trust, employee benefit plan, individual retirement account, Keogh Plan
or other tax-exempt entity, it is authorized and qualified to become an investor
in  the  Company  and  subsequently,   Chiste,   and  the  person  signing  this
Subscription Agreement on behalf of such entity has been duly authorized by such
entity to do so.

      9.7. No Offer Until  Determination of Suitability.  I acknowledge that any
delivery to me of the  documents  relating to the offering of the Units prior to
the  determination by the Company of my suitability will not constitute an offer
of the Units until such determination of suitability is made.

      9.8. For Florida Residents.  None of the Units, Preferred Stock and Common
Stock have been registered under the Securities Act of 1933, as amended,  or the
Florida Securities Act, by reason of specific exemptions  thereunder relating to
the limited availability of the offering.  The Units, Preferred Stock and Common
Stock  cannot be sold,  transferred  or  otherwise  disposed of to any person or
entity  unless  subsequently  registered  under the  Securities  Act of 1933, as
amended,  or the Securities Act of Florida,  if such  registration  is required.
Pursuant to Section  517.061(11) of the Florida  Securities  Act, when sales are
made to five  (5) or  more  persons  in  Florida,  any  sale  made  pursuant  to
Subsection  517.061(11)  of the Florida  Securities Act will be voidable by such
Florida   purchaser   either  within  three  days  after  the  first  tender  of
consideration is made by the purchaser to the issuer, an agent of the issuer, or
an escrow agent, or within three days after the availability of the privilege is
communicated to such purchaser, whichever occurs later. In addition, as required
by  Section   517.061(11)(a)(3),   Florida  Statutes  and  by  Rule  3-500.05(a)
thereunder,  if I am a  Florida  resident  I may  have,  at the  offices  of the
Company,  at  any  reasonable  hour,  after  reasonable  notice,  access  to the
materials set forth in the Rule that the Company can obtain without unreasonable
effort or expense.

      9.9. Third Party  Beneficiary.  Chiste is a third party beneficiary of the
representations of the Investor in this Section 9.

10. Company  Representations.  The representations and warranties of the Company
set forth in the  Exchange  Agreement  being  made to Chiste,  are  incorporated
herein  by  reference,  and may be  relied  upon by the  Investor  as if made to
directly to the Investor as of the Closing, subject to any modifications made to
the Exchange Agreement in respect of such  representations  and warranties prior
to or as of the Closing.

                                       7
<PAGE>

11. Indemnification.

            (a) The Company  hereby  agrees to indemnify  and hold  harmless the
Investor and any of its officers, directors, stockholders, employees, agents and
attorneys against any and all losses, claims, demand, liabilities,  and expenses
(including  reasonable  legal or other expenses  incurred by each such person in
connection  with  defending  or  investigating  any such claims or  liabilities,
whether or not resulting in any liability to such person or whether  incurred by
the  indemnified  party in any action or proceeding  between the  indemnitor and
indemnified party or between the indemnified party and any third party) to which
any such indemnified party may become subject,  insofar as such losses,  claims,
demands,  liabilities and expenses (a) arise out of or are based upon any untrue
statement or alleged untrue statement of a material fact made by the Company and
contained  herein or  incorporated by reference or (b) arise out of or are based
upon any breach by the Company of any representation, warranty or agreement made
by them and contained herein or incorporated by reference.

            (b) I hereby  agree to  indemnify  and hold  harmless  the  Company,
Chiste and  Battenkill,  their  respective  officers,  directors,  stockholders,
employees,  agents and attorneys  against any and all losses,  claims,  demands,
liabilities, and expenses (including reasonable legal or other expenses incurred
by each such person in  connection  with  defending  or  investigating  any such
claims or liabilities,  whether or not resulting in any liability to such person
or whether incurred by the indemnified party in any action or proceeding between
the indemnitor and indemnified  party or between the  indemnified  party and any
third party) to which any such indemnified party may become subject,  insofar as
such losses, claims,  demands,  liabilities and expenses (a) arise out of or are
based upon any untrue  statement or alleged untrue  statement of a material fact
made by me and contained herein or (b) arise out of or are based upon any breach
by me of any representation,  warranty or agreement made by me contained herein.
Each of Chiste and Battenkill is a third-party beneficiary of this Section 11(b)
and this Section 11(b) may not be modified or amended  without the prior written
agreement of Chiste.

12. Voting Agreement.

            (a) During the period  commencing on the Closing and  terminating on
the one year  anniversary of the Closing,  each  Investor,  in its capacity as a
shareholder of Chiste,  either by reason of the Preferred  Stock or Common Stock
(together the "Voting  Shares"),  agrees to vote or cause to be voted all Voting
Shares  directly or indirectly  owned by the Investor or over which the Investor
has the  beneficial  ownership or the right to vote and all Voting  Shares which
the Investor acquires directly or indirectly or has the beneficial  ownership or
right to vote in the future,  at any meeting of the shareholders of Chiste,  and
in any action by written consent of the  shareholders  of Chiste,  in favor of a
nominee of Keating Reverse Merger Fund, LLC ("KRM") to the board of directors of
Chiste and will not vote or cause to be voted for the removal  from the board of
directors  of the nominee of KRM. If the nominee of KRM is removed or  otherwise
retires or resigns,  then the Investor will act in accordance with the above for
any replacement  nominee of KRM. The Investor agrees that the board of directors
of Chiste will consist of five  persons  during the term of this  provision  and
will take all such  action so as to retain  the board at such  number,  provided
that the number of directors may only be increased or decreased with the written
consent of KRM.

            (b) During the period  commencing on the Closing and  terminating on
the one year  anniversary of the Closing,  each  Investor,  in its capacity as a
shareholder of Chiste,  by reason of the Voting Shares,  agrees to vote or cause
to be voted all Voting Shares  directly or  indirectly  owned by the Investor or
over which the  Investor has the  beneficial  ownership or the right to vote and
all Voting Shares which the Investor  acquires directly or indirectly or has the
beneficial  ownership  or right to vote in the  future,  at any  meeting  of the
shareholders of Chiste, and in any action by written consent of the shareholders
of  Chiste,  (a) to approve a 1 for 25 reverse  stock  split of the  outstanding
Common  Stock of  Chiste,  with  special  treatment  for  certain  of the Chiste
shareholders  to  preserve  round lot  stockholders  ("Reverse  Split"),  (b) to
approve the change of the corporate  name from Chiste to one  recommended by the
board of directors to reflect the  acquisition of the Company  ("Name  Change"),
and (c) all other actions as shall be necessary or desirable in connection  with
or related to the foregoing,  including without limitation, any amendment to the
articles of incorporation of Chiste to effect the foregoing.

                                       8
<PAGE>

            (c) Each  investor,  by this  provision,  with respect to the Voting
Shares over which it has voting  authority  and any Voting  Shares over which it
may have voting authority in the future, does hereby irrevocably  constitute and
appoint Joshua Tosteson and /or Andrew Thomas,  acting  individually or jointly,
or any nominee,  with full power of substitution,  as his or its true and lawful
attorney and proxy, for and in his or its name, place and stead, to vote or give
a consent in respect  of each  Voting  Shares  the  Investor's  proxy,  at every
annual,  special or adjourned  meeting of the shareholders of Chiste  (including
the right to sign his or its name as a shareholder  to any consent,  certificate
or other  document  relating  to Chiste  that may be  permitted  or  required by
applicable law in respect of the voting of or consenting by the  shareholders of
Chiste) in favor of the adoption and approval of the Reverse Split,  Name Change
and other actions set forth in subpart (c) of paragraph  (b) of this  provision.
Each Investor shall perform all such other acts and execute all other  documents
and instruments as may be reasonably required to vest in the lawful attorney and
proxy and Chiste to carry out the provisions of this provision.

            (d) The obligations of each Investor  pursuant to paragraphs (b) and
(c) of this  Section 12, will  terminate  upon the  consummation  of the Reverse
Split and Name Change, including through the time of the filing of the amendment
to the articles of incorporation of Chiste.

            (e) If any Investor or any of its  affiliates or nominee is a member
of the board of  directors  or an officer of Chiste,  nothing in this Section 12
will be deemed to limit or restrict the director or officer acting in his or her
capacity as a director or officer of Chiste,  as the case may be, and exercising
his or her fiduciary duties and responsibilities, it being agreed and understood
that this  Section 12 shall  apply to the  Investor  solely in his or her or its
capacity as a  shareholder  and not to his,  her or its  actions,  judgments  or
decisions as a director or officer of Chiste.

13. Joinder Provision for LLC Operating Agreement.

            (a) The  Investor  hereby  agrees that the  membership  units of the
Company  acquired in this offering are subject to the terms and conditions of an
Operating  Agreement  dated as of  November  11,  2001 (as  amended by the First
Amendment to the Operating  Agreement dated May 14, 2004, and as further amended
by the Second Amendment to the Operating Agreement dated May 9, 2005 ("Operating
Agreement"),  by and among the Company and its  members.

            (b)  The  Investor  has  reviewed  and   understands  the  Operating
Agreement and has the power to join in such  agreement and to grant the power of
attorney set forth herein in Section 15, and upon such  signature  and delivery,
this Agreement and the power of attorney will  constitute  the Investor's  valid
and binding obligation, enforceable in accordance with its terms.

            (c)  The  Investor  hereby  agrees  to be  bound  by  the  Operating
Agreement as if the Investor were an original  signatory  thereto.  The Investor
acknowledges and understands that for purposes of the Operating  Agreement,  the
Investor  shall  have  the same  rights  and  obligations  under  the  Operating
Agreement  as the other  members of the  Company,  proportionate  to  Investor's
membership  interest  as  between  the  Investor  and the other  members  of the
Company, unless otherwise agreed in writing by the members of the Company.

                                       9
<PAGE>

14. Accession Agreement to Exchange Agreement.

            (a) Other than as provided in this Subscription Agreement, no person
has any right to acquire, or has any other interest in, the Units being acquired
hereunder, and there are no voting trusts, or other agreements or understandings
with respect to the ownership or voting of the Units or the Preferred Stock into
which they will be exchanged or the Common Stock into which the Preferred  Stock
will be converted.

            (b) The Investor  has the power to sign and deliver  this  Agreement
and grant the power of  attorney  set forth  herein in Section 15, and upon such
signature and delivery, this Agreement and the power of attorney will constitute
the Investor's valid and binding obligation,  enforceable in accordance with its
terms.

            (c)  The  Investor  has  reviewed  and   understands   the  Exchange
Agreement,  and the  representations  of the Investor set forth therein are true
and correct as of the date hereof and will be true and correct as of the closing
of the Exchange Agreement.

            (d) By signing  and  delivering  this  Subscription  Agreement,  the
Investor  agrees to be a party to, and bound by the terms and conditions of, the
Exchange  Agreement.  In particular,  the Investor agrees to the indemnification
provisions  in favor of Chiste set forth in the Exchange  Agreement  under which
Chiste  will be  entitled  to  damages  from a  breach  of the  representations,
warranties,  covenants  and  agreements  of the other members of the Company and
those of the Company.

(e) In  connection  with the  exchange,  the Company is authorized to deliver to
Chiste such documents as it requires to transfer the Units to Chiste pursuant to
the  Exchange  Agreement.

15. Power of Attorney for  Operating  Agreement and Exchange  Agreement.  Joshua
Tosteson  and Leo Blomen,  and each of them,  are hereby  irrevocably  appointed
attorney-in-fact  and  authorized  and empowered to act for and on behalf of the
Investor  (each with full power of  substitution  in the premises) in connection
with (i) the Operating Agreement and any actions necessary  thereunder to effect
the terms of the Exchange  Agreement  including  execution of the aforementioned
agreements,  (ii) the  exchange of  membership  units  pursuant to the  Exchange
Agreement,  (c) the notice and the  indemnification  provisions  of the Exchange
Agreement,  (d) this  Subscription  Agreement  and (e) such other matters as are
reasonably  necessary  for the  consummation  of the Exchange  Agreement and the
transactions  contemplated  by the  Exchange.  By the execution  hereof,  Joshua
Tosteson and Andrew Thomas each hereby  accepts such  appointment  and agrees to
act as the  representative  of the Investor within the power of the appointment.
The Investor,  by the execution hereof,  confirms such appointment and authority
and  acknowledges  and agrees that such  appointment is irrevocable  and coupled
with an interest,  it being  understood  that the willingness of the Company and
Chiste to enter into the Exchange Agreement and exchange the Preferred Stock for
the Units is based,  in part, on the appointment of a  representative  to act on
behalf of the Investor.

16.  Severability;  Remedies.  In the  event  any  parts  of  this  Subscription
Agreement are found to be void,  the remaining  provisions of this  Subscription
Agreement are nevertheless binding with the same effect as though the void parts
were deleted.

17. Governing Law and Jurisdiction.  This Subscription  Agreement will be deemed
to have been made and delivered in New York, New York and will be governed as to
validity, interpretation,  construction, effect and in all other respects by the
internal  laws of the State of New York.  Each of the Company  and the  Investor
hereby (i) agrees that any legal suit,  action or  proceeding  arising out of or
relating to this  Subscription  Agreement will be instituted  exclusively in the
state  courts of New York,  in the County of New York,  or in the United  States
Southern  District  Court  located in New York City,  New York,  (ii) waives any

                                       10
<PAGE>

objection to the venue of any such suit,  action or proceeding  and the right to
assert  that  such  forum is not a  convenient  forum for such  suit,  action or
proceeding,  (iii)  irrevocably  consents  to  the  jurisdiction  of  the  above
mentioned courts in any such suit,  action or proceeding,  (iv) agrees to accept
and  acknowledge  service of any and all process  that may be served in any such
suit,  action or proceeding in the above mentioned  courts,  and (v) agrees that
service of process upon it mailed by certified  mail to its address set forth on
my signature page will be deemed in every respect  effective  service of process
upon it in any suit, action or proceeding.

18.  Counterparts.  This  Subscription  Agreement may be executed in one or more
counterparts, each of which will be deemed an original but all of which together
will constitute one and the same instrument.  The execution of this Subscription
Agreement may be by actual or facsimile signature.

19. Benefit.  Except as otherwise set forth herein, this Subscription  Agreement
is binding  upon and inures to the  benefit of the parties  hereto (and  Chiste,
Battenkill and KRM to the extent one or all of them is a third-party beneficiary
hereof)  and  their  respective  heirs,  executors,   personal  representatives,
successors  and  assigns.  Chiste,  Battenkill  and KRM  each  is a  third-party
beneficiary  with respect to any sections hereof that so state or that otherwise
indicate  that  Chiste,  Battenkill  and KRM  would be  entitled  to rely on the
representations, warranties or covenants made by the Investor therein.

20.  Notices.  All  notices,  offers,  acceptance  and any other acts under this
Subscription  Agreement (except payment) must be in writing, and is sufficiently
given if delivered to the addressees in person,  by overnight  courier  service,
or, if mailed,  postage prepaid,  by certified mail (return receipt  requested),
and will be effective  three days after being  placed in the mail if mailed,  or
upon  receipt or refusal of receipt,  if delivered  personally  or by courier or
confirmed telecopy,  in each case addressed to a party. All communications to me
should  be sent to my  preferred  address  on the  signature  page  hereto.  All
communications to the Company should be sent to:

                           HydroGen, LLC
                           1801 Route 51South
                           Jefferson Hills, Pennsylvania  15025
                           Attn:  Joshua Tosteson
                           Tel:  ()
                           Fax: ()

and                        Battenkill Capital, Inc.
                           7252 Main Street, Building A, Suit A
                           PO Box 2528
                           Manchester Center, VT 05255
                           Attn:  Robyn Harrington
                           Tel.: (802) 549-5400
                           Fax: (802) 549-5401

21. Oral Evidence.  This Subscription Agreement constitutes the entire agreement
between the parties with respect to the subject matter hereof and supersedes all
prior oral and written agreements between the parties hereto with respect to the
subject matter hereof. This Subscription  Agreement may not be changed,  waived,
discharged,  or terminated  orally,  but rather,  only by a statement in writing
signed by the party or parties against which enforcement or the change,  waiver,
discharge or termination is sought.

22. Section  Headings.  Section headings herein have been inserted for reference
only and will not be deemed to limit or otherwise  affect,  in any matter, or be
deemed to interpret in whole or in part,  any of the terms or provisions of this
Subscription Agreement.

23. Survival of Representations, Warranties and Agreements. The representations,
warranties and agreements contained herein will survive the delivery of, and the
payment for, the Units and exchange of the Units for the Common Stock.

                                       11
<PAGE>

24.  Acceptance  of  Subscription.  The  Company  may accept  this  Subscription
Agreement at any time for all or any portion of the securities subscribed for by
executing a copy hereof as provided and  notifying  me within a reasonable  time
thereafter.

                                       12
<PAGE>

================================================================================

ALL INVESTORS  MUST SIGN              The foregoing subscription is accepted and
AND PRINT NAME BELOW                  hereby agrees to be bound by its terms.

Signature:__________________________
Print Name:_________________________  HYDROGEN, LLC

Date:_______________________________
                                      By: ______________________________________
Signature:__________________________  Print Name: Joshua Tosteson
Print Name:_________________________  Title: Manager

Date:_______________________________  Date: July 7, 2005

================================================================================

                                       13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00087-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00087-of-00352.parquet"}]]